AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05166330
Drug: Ketofol 1:3 ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).
Trial: NCT06169046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT06016465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo pills
Trial: NCT05570292
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
Trial: NCT06254612
Drug: SP-624
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of two capsules totaling 20 mg/day
Trial: NCT06254612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of two matching placebo capsules
Trial: NCT04925661
Drug: HEC53856
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either dose of HEC53856 will be administered after fasting .
Trial: NCT04925661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either dose of placebo will be administered after fasting .
Trial: NCT03743194
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
Trial: NCT03743194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to standard analgesia technique will be given pain medications.
Trial: NCT05198804
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c3 will be administered.
Trial: NCT02124226
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg/week + folic acid the day after
Trial: NCT02124226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT04049851
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
Trial: NCT06295302
Drug: HWH486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HWH486 capsule was administrated orally
Trial: NCT06295302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was administrated orally
Trial: NCT05236530
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Trial: NCT06559969
Drug: Intravenous administered opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
Trial: NCT05438797
Drug: Adoptive TIL-TCM transfer therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
Trial: NCT06141070
Drug: Standard systemic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy or immunotherapy
Trial: NCT05262101
Drug: TQB2858 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
Trial: NCT05921890
Drug: GS3-007 oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage was calculated according to body weight, once a day or twice a day.
Trial: NCT06180720
Drug: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
Trial: NCT06180720
Drug: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Trial: NCT05639647
Drug: ATM-AVI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug specifically designed to treat resistant gam-negative bacterial infections
Trial: NCT05295589
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05814835
Drug: 2-4 mCi 68Ga/64Cu-FAPI-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
Trial: NCT05814835
Drug: 4-6 mCi 68Ga/64Cu-FAPI-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
Trial: NCT05814835
Drug: 6-8 mCi 68Ga/64Cu-FAPI-XT117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
Trial: NCT06158269
Drug: DVRd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
Trial: NCT00431548
Drug: 100% O2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06093425
Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All medications administered intravenously
Trial: NCT06093425
Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All medications administered intravenously
Trial: NCT06525168
Drug: DA414 Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
Trial: NCT06525168
Drug: DA414 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
Trial: NCT03953170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05486026
Drug: Nonsteroidal Antiinflammatory Drug
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient in this second group will receive NSAID for 3 weeks
Trial: NCT06026397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
Trial: NCT04789499
Drug: Theophylline Powder
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
Trial: NCT04789499
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
Trial: NCT06441578
Drug: Recombinant ADAMTS13
RxNorm normalized name: ADAMTS13, recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant ADAMTS13, Intravenous injection
Trial: NCT04929483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05631626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05003648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05369767
Drug: SAD, SHR-2004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose
Trial: NCT05369767
Drug: SAD, SHR-2004 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dose
Trial: NCT05909267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients and healthy controls will receive one time administration of Placebo.
Trial: NCT03564548
Drug: PPP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group assigned to PPP001
Trial: NCT04999488
Drug: BPM31510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Trial: NCT04440592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05064319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
Trial: NCT04897802
Drug: Experimental: GLP1-RA (exenatide) administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
Trial: NCT05123196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05593588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
Trial: NCT04933565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules
Trial: NCT05412082
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Trial: NCT05412082
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
Trial: NCT05318326
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Trial: NCT05318326
Drug: Yogliptin 400mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Trial: NCT05318326
Drug: Yogliptin 200mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Trial: NCT04502433
Drug: CUROSURF® (poractant alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW.
Trial: NCT06228339
Drug: Xatral® XL 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xatral® XL 10 mg (Reference Drug)
Trial: NCT05397652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
Trial: NCT05559268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Trial: NCT03797612
Drug: Placebo 6 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative intrathecal injection
Trial: NCT04674956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 200mg, D1; every 21 days as a cycle.
Trial: NCT05917340
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering dose of dexamethasone or prednisolone upto 8 weeks
Trial: NCT05389267
Drug: Kinezodianone R hydrochloride
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyedrops
Trial: NCT05389267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05107115
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use
Trial: NCT05560360
Drug: SHR1459 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/tablet; administered orally
Trial: NCT06403943
Drug: BaiDiZiYin Pill, ShenQiYiFei Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating.
Trial: NCT06403943
Drug: Anti tuberculosis chemotherapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
Trial: NCT04479072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Trial: NCT04617171
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
Trial: NCT06556732
Drug: Eplereone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Trial: NCT05833815
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GemOx or CapOx
Trial: NCT06064812
Drug: FWD1802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.
Trial: NCT05481307
Drug: RLD2203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period
Trial: NCT05166876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days
Trial: NCT05363774
Drug: NNC0519-0130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.
Trial: NCT05363774
Drug: Placebo (NNC0519-0130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.
Trial: NCT04908748
Drug: Esflurbiprofen Hydrogel Patch
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esflurbiprofen is a cyclooxygenase (COX) inhibitor
Trial: NCT05607615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5N saline as an intravenous (IV) infusion once every 28 days
Trial: NCT04862819
Drug: new local drug delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
Trial: NCT06129838
Drug: [11C]-CS1P1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
Trial: NCT06559150
Drug: Nebulized Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
Trial: NCT00486772
Drug: Sevelamer (Renagel), calcium acetate (Phos-ex)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04117165
Drug: Patient Current Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
Trial: NCT04970355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syring; s.c. injection
Trial: NCT06381063
Drug: pain management
RxNorm normalized name: Olu Pain Management 4%-1% Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
Trial: NCT06381063
Drug: ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
Trial: NCT06381063
Drug: PLacebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day, during 48 h after surgery, intravenous administration
Trial: NCT05368623
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
Trial: NCT05460065
Drug: single E4 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
Trial: NCT05460065
Drug: single E4 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single i.v. infusion of E4 100 mg (n=6)